Ribo Biopharma and Qilu Pharma Enter into Licensing Agreement for Anti-PCSK9 siRNA Drug RBD7022 in Greater China

Dr. Tao Weikang, Vice President of Qilu Pharmaceutical Group and General Manager of the Global Innovation Research and Development System, stated:"Qilu Pharmaceutical is striving to build an industry-leading innovative drug R&D pipeline. We are continuously making efforts in the field of chronic disease treatment, including cardiovascular diseases, and constantly expanding and improving our product pipelines in different therapeutic areas to address unmet clinical needs. Ribo Life Science is a leader in China's small nucleic acid pharmaceuticals. We are very pleased to collaborate with Ribo Life Science, using local innovation to benefit a wide range of Chinese patients. We look forward to a strong partnership with Ribo Life Science in the small nucleic acid field, rapidly advancing this highly promising innovative drug to market, tapping into the Chinese market, and achieving win-win cooperation."

Dr. Zicai Liang, founder and CEO of Ribo Life Science, stated:"Ribo Life Science has globally competitive capabilities and a rich R&D pipeline layout in the cardiovascular metabolism field. We are very pleased to reach this collaboration with Qilu Pharmaceutical. Qilu Pharmaceutical possesses outstanding new drug transformation and commercialization capabilities, and we believe that this cooperation will significantly accelerate the clinical development and commercialization process of RBD7022, bringing innovative small nucleic acid therapies to Chinese patients as soon as possible."

Qilu Pharmaceutical Group is a leading full-industry-chain pharmaceutical company, with 11 major production bases across China, covering a total area of 8,916 mu, and ranked fifth on the 2022 China Pharmaceutical Industry Top 100 list.

Relying on the five major R&D centers in China and the United States, the group focuses on clinical value and patient-centeredness, continuously integrating high-quality global resources for innovative drug development. In 2022, the group's R&D investment accounted for approximately 11% of its sales revenue. It has established a rich and competitive or differentiated product pipeline in significant unmet disease areas such as oncology, infectious diseases, liver diseases, autoimmune conditions, and metabolic disorders, along with multiple competitive platforms. The group actively introduces external innovation projects and collaborates with academic institutions, integrating and innovating with all parties to promote the rapid market entry of more high-quality drugs through warm-hearted scientific and technological innovation, driving a better and healthier future for humanity.

Suzhou Ribo Life Science Co., Ltd. (referred to as "Ribo Life Science") was established in 2007. It is an innovative R&D company dedicated to developing RNA interference (RNAi) drugs and is a major pioneer and leader in China's small nucleic acid technology and small nucleic acid pharmaceutical industry. The company's headquarters is located in Kunshan, Jiangsu, with R&D centers in Beijing and Gothenburg, Sweden.

Ribo Life Science benchmarks the innovative frontier of international small nucleic acid technology, committing to the iterative research and development of small nucleic acid chemical modification and drug delivery technologies. It has established an autonomous and controllable, fully integrated small nucleic acid drug R&D platform that supports the entire lifecycle of small nucleic acid drugs from early-stage research to industrialization. Its self-developed GalNAc small nucleic acid drug delivery technology platform is named RIBO-GalSTAR.^®Highly specific liver targeting, high efficiency, and long-lasting characteristics with international competitive standards.